Powder: -20°C for 3 years
In solvent: -80°C for 2 years
CCG-100602 inhibits RhoA/C-mediated, SRF-driven luciferase expression in PC-3 prostate cancer cells (IC50 :9.8 μM).
Description | CCG-100602 inhibits RhoA/C-mediated, SRF-driven luciferase expression in PC-3 prostate cancer cells (IC50 :9.8 μM). |
In vitro | CCG-100602 blocks the expression of MRTF-A/SRF-activated genes. CCG-100602 (3-30?μM) decreases the number of adherent hASC cells[1]. |
Synonyms | CCG 100602, Inhibitor, transcription, inhibit, serum, myocardin, nuclear, SRF, CCG100602, MRTF-A, CCG-100602, Ras, localization |
Molecular Weight | 478.82 |
Formula | C21H17ClF6N2O2 |
CAS No. | 1207113-88-9 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
DMSO: 100 mg/mL (208.85 mM), Need ultrasonic
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.